Article Text

other Versions

PDF
Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study
  1. Margaret A Greven1,2,
  2. Sunir Garg1,
  3. Bing Chiu3,
  4. Sumit P Shah3,4,
  5. Jeremy Wolfe5,
  6. Howard F Fine3,4,
  7. Daniel B Roth3,4,
  8. Joshua Robinson6,
  9. Jacob Mong7,
  10. Jason Hsu1,
  11. Carl Regillo1,
  12. Allen Ho1,
  13. Julia A Haller1
  1. 1Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA
  2. 2Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA
  3. 3Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
  4. 4NJ Retina, New Brunswick, New Jersey, USA
  5. 5Associated Retinal Consultants, Royal Oak, Michigan, USA
  6. 6Emory Eye Center, Atlanta, Georgia, USA
  7. 7Eye Clinic of Wyandotte, Wyandotte, Michigan, USA
  1. Correspondence to Dr Sunir Garg, MidAtlantic Retina, The Retina Service of Wills Eye Hospital, 840 Walnut Street, Suite 1020, Philadelphia, PA 19107, USA; sgarg{at}midatlanticretina.com

Abstract

Background/aims To describe the results of pars plana vitrectomy (PPV) for persistent symptomatic vitreomacular traction (VMT) with or without macular hole (MH) after intravitreal ocriplasmin injection.

Methods Multicentre retrospective study of eyes that received intravitreal ocriplasmin between January 2013 and January 2014 for symptomatic VMT with or without MH, and then went on to PPV (ocriplasmin-treated group) for persistent pathology, compared with a control group of patients with symptomatic VMT with or without MH who were offered ocriplasmin injection but proceeded directly to PPV (PPV-only group). Intraoperative characteristics, visual acuity (VA) outcomes and spectral-domain optical coherence tomography images were reviewed for the two groups. Primary outcome measure was VA after PPV.

Results 51 eyes of 51 patients underwent PPV after receiving ocriplasmin, and 22 eyes of 22 patients proceeded directly to PPV. Although VA was significantly better at all time points in the PPV-only compared with the ocriplasmin-treated group, at 3 and 6 months after PPV both groups had similar amount of visual improvement. Both groups had similar rates of pathology resolution; 50/51 (98%) eyes in the ocriplasmin group and 22/22 (100%) eyes in the PPV-only group had release of VMT and/or MH closure after PPV. The two groups had similar PPV-related complication rates.

Conclusions Eyes with persistent symptomatic VMT and/or MH have similarly high rates of pathology resolution as well as similar VA gains regardless of whether they received ocriplasmin prior to PPV.

  • Macula
  • Vitreous
  • Retina

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas